We found an inverse correlation between MCT1 and 4 mRNA expression levels in blasts of AML patients and showed that only MCT4 high mRNA level is correlated with poor prognosis in AML patients, as previously described for CD147 (22), thus indicating MCT4 as a potential therapeutic target in AML. This evidence concerns the gene BSG and acute myeloid leukemia.